期刊文献+

局部晚期乳腺癌的保留乳房手术 被引量:2

Breast conservation therapy in locally advanced breast cancer patients
暂未订购
导出
摘要 乳腺癌是女性最常见的恶性肿瘤之一,局部晚期乳腺癌(LABC)的治疗是世界范围内的临床难题,影响着乳腺癌总体生存率的提高。LABC的涵盖范围伴随着TNM分期系统的修订而不断变化。已有的研究证明,新辅助化疗后可以进行保留乳房手术(BCT),但要严格掌握适应证,保留乳房手术的指征已逐渐取得共识。开始治疗之前准确记录或定位肿瘤,要保证足够的阴性切缘。对于腋窝淋巴结手术问题仍有争议,多数主张常规进行清除手术。预后上不差于早期乳腺癌作保留乳房手术后的局部复发率。 Breast cancer is one of the most common malignant tumors in women. The treatment of locally advanced breast cancer (LABC) is a tough clinical problem in the world and hampering to improve the overall survival of breast cancer patients. Followed the revises of TNM staging system for breast cancer, the classification of LABC has been kept alternating continuously for decades. Previously finished studies presented that breast conservation therapy (BCT) may be carried out in locally advanced breast cancer patients after neoadjuvant chemotherapy, but the indication should be controlled strictly. The indication of BCT has been made an agreement gradually. BCT should record and mark the preoperative edge and position of tumors exactly, and ensure adequate negative cutting edges. Inregard to axillary lymph node dissection, the argument still remains by now, and most of authors suggested to complete axillary clearance conventionally. The local recurrence of breast conservation therapy in LABC patients is not worse than that in early breast cancer patients.
出处 《中华肿瘤防治杂志》 CAS 2007年第20期1591-1594,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤/外科学 保留乳房 综述文献 breast neoplasms/surgery breast conservation therapy review literature
  • 相关文献

参考文献3

二级参考文献29

  • 1傅俊惠,柯斌,杨楚徐,黄培生,黄建豪,郑海波,郑春鹏,吴智勇.保留皮肤及乳头乳晕的皮下乳腺癌改良根治术同期乳房重建32例报告[J].中国实用外科杂志,2005,25(1):54-55. 被引量:20
  • 2秦贤举,陈君雪,张宏伟,赵大方,张华,罗文杰,黄倩,练士贤,童汉兴.女性乳腺癌216例保乳手术及其综合治疗的临床研究[J].世界肿瘤杂志,2005,4(2):109-111. 被引量:4
  • 3王靖,王翔,晏晓青,由磊.乳腺癌改良根治术后同时应用腹壁下动脉穿支皮瓣游离移植再造乳房[J].中华医学杂志,2005,85(47):3359-3361. 被引量:8
  • 4陈君雪,阴忆青,张华,朱玮.早期乳腺癌保乳手术247例报告[J].外科理论与实践,2006,11(2):112-114. 被引量:17
  • 5Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344:783-792.
  • 6Cook-Bruns N. Retrospective analysis of the safety of Hereeptin immunotherapy in metastatic breast cancer. Oncology, 2001,61:S58-S66.
  • 7Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17:2235-2249.
  • 8Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage Ⅱ or Ⅲ breast cancer: a pilot study. J Clin Oncol, 2003, 21:46-53.
  • 9Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer, 2003, 4:348-353.
  • 10Schiffhauer LM, Griggs JJ, Ahrendt GM, et al. Docetaxd and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol, 2003, 22:242.

共引文献30

同被引文献18

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部